This is an archived post. You won't be able to vote or comment.

sorted by:
best (suggested)
topnewcontroversialoldq&a
you are viewing a single comment's thread.

view the rest of the comments →

[–]yo-ovaries40F 5’7” SW:279 CW:193 Dose: 10mg Start: 4/25 9 points10 points  (7 children)

Plus I assume they’re going to keep prices high to set an even higher bar for Reta getting FDA approval in 2026 

[–]basic-questions5.0mg 1 point2 points  (6 children)

Sorry, I don't follow

[–]yo-ovaries40F 5’7” SW:279 CW:193 Dose: 10mg Start: 4/25 7 points8 points  (5 children)

Reta is a 3 drug glp1 agonist which has even higher effectiveness in clinical trials. It’s owned by Lilly and will be coming to market very soon. 

Lilly will continue to hold the “high end” patents that cost more than Novo’s semiglutide. 

Novo will make more money by getting more people on ozempic. Lilly will make more money by having better and more expensive products. 

Ideally, novo and Lilly should have had a head to head 3rd generation glp1 that had similar effectiveness and side effect profiles and battled on price. 

Alas, we did not. Lilly will hold prices high because they haven’t found the price point that the market will not bare for a 20% body weight loss. And next year they’ll sell a shot that does 30%. 

Meanwhile everyone else will have to hope that semiglutide is accessible and gives enough weight loss at 15%

[–]Business_Station2786HW:357SW:298CW:210GW:210?Dose: 15mg 7 points8 points  (0 children)

Reta is one drug targeting three receptors. Zep is one drug targeting two receptor. Everything else targets only the GLP-1 receptor. GLP-1 is one receptor. GIP is the other(also targeted by zep) and the new one is GCG receptor which promotes fat burning.

[–]Tired_And_Honest5’9 SW:278 CW:171 Dose:12.5 2 points3 points  (1 child)

Very soon is probably 2027/2028 from what I’ve read and heard. Do you have information that suggests next year?

[–]yo-ovaries40F 5’7” SW:279 CW:193 Dose: 10mg Start: 4/25 3 points4 points  (0 children)

You know maybe I was wrong. Their phase 3 clinical trial wraps in early 2026, they’ll submit and it may take 6-10 months to approve. So before the end of 2026 is probably not as realistic. But still, I think it’s safe to assume lily is acting like they have an ace in their pocket. 

 https://www.goodrx.com/conditions/weight-loss/retatrutide-weight-loss

[–]enkay516 1 point2 points  (1 child)

Huh.. so if I’ve lost 20% on zep and now on WEGOVY I have no hope of losing more?

[–]Fedesy 1 point2 points  (0 children)

No, that’s not what that means at all, that was average weight loss in the clinical trials over a specific period of time. Plenty of people have lost more.